Prelude Therapeutics Inc
For the period ended Mar 31, 2026. Filed May 12, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 12, 2026
PRLD$3.76+4.4%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Changes in Stockholders’ Equity (Unaudited)
STATEMENTS OF CHANGES INSTOCKHOLDERS’ EQUITY
| Voting common stock · Non-voting commonstock · Additional paid-in · Accumulated other comprehensive · Accumulated | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| (in thousands, except shares) · Shares · Amount · Shares · Amount · capital · income (loss) · deficit · Total | |||||||||||
| Balance at January 1, 2026 | 48,225,493 | $5 | 14,728,135 | $1 | $751,684 | $8 | $(683,061) | $68,637 | |||
| Issuance of common stock upon vesting of RSUs, net of 21,426 shares withheld for employee taxes | 64,594 | — | — | — | (20) | — | — | (20) | |||
| Unrealized loss on marketable securities, net of tax | — | — | — | — | — | (49) | — | (49) | |||
| Stock-based compensation expense | — | — | — | — | 2,000 | — | — | 2,000 | |||
| Net loss | — | — | — | — | — | (10,385) | (10,385) | ||||
| Balance at March 31, 2026 | 48,290,087 | $5 | 14,728,135 | $1 | $753,664 | $(41) | $(693,446) | $60,183 | |||
| Voting common stock · Non-voting common stock · Additional paid-in · Accumulated other comprehensive · Accumulated | ||||||||
|---|---|---|---|---|---|---|---|---|
| (in thousands, except shares) | Shares | Amount | Shares | Amount | capital | income (loss) | deficit | Total |
| Balance at January 1, 2025 | 42,298,859 | $4 | 12,850,259 | $1 | $714,982 | $35 | $(583,563) | $131,459 |
| Issuance of common stock upon vesting of RSUs, net of 3,859 shares withheld for employee taxes | 5,516 | — | — | — | (5) | — | — | (5) |
| Issuance of common stock upon exercise of prefunded warrants | 1,299,827 | — | — | — | — | — | — | — |
| Unrealized loss on marketable securities, net of tax | — | — | — | — | — | (23) | — | (23) |
| Stock-based compensation expense | — | — | — | — | 3,832 | — | — | 3,832 |
| Net loss | — | — | — | — | — | — | (32,085) | (32,085) |
| Balance at March 31, 2025 | 43,604,202 | $4 | 12,850,259 | $1 | $718,809 | $12 | $(615,648) | $103,178 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.